Member Info for dactions

I agree Trek - this is the year it will happen.

The RNS specifies all the achievements that we alredy knew of course but for new investors puts all the info in one place. Doubters, I include myself at times even though I've been a shareholder for some years, will ask about the revenue. We have in SOH's statement:

"As existing deals contribute to full year revenues, partners continue to grow sales with new product launches in 2019, and as new agreements continue to be signed we anticipate further revenue growth in 2019."

More concrete news on that score would help us all.

Today's RNS is quite an announcement for TPG. I like the fact it encompases several TPG divisions for the work.

Will this budge the market cap upwards ?

Thanks for link - it shows a full graph of where the SP has gone over the years including accounting for the 100:1 consolidation.

Could only find bare bones comments on yesterday's Retinal & Gene Therapy conference in Vancouver. Dr Jason Comander gave a 15 mins slot like all other particpants, which included the recent positive results of RENE's 1st cohort of the Phase 2a study.

Interesting for me though is Dr Comander has operated on patients with RP using the FDA approved 'Luxturna' gene therapy marketed by Spark Therapeutics. The one that costs $425,000 per eye or effectively $850,000 as both eyes are done. He has spoken at other conferences on RP including specifically about 'Luxturna' so to my mind he is the perfect person to have spoken on Reneuron's study results.

Here are the links to the two updates from Edison Research - they've always been quietly positive on RENE.

Headline: Long-awaited Partnering Floodgates open
ReNeuron Group 11 April 2019 Update
Edison Research link:
https://www.edisongroup.com/publication/long-awaited-partnering-floodgates-open/23916

Headline: Early clinical data in RP continue to improve
ReNeuron Group 26 April 2019 Flash note
Edison Research link:
https://www.edisongroup.com/publication/early-clinical-data-in-rp-continue-to-improve/24020

Here's Edison Research's take on the recent Chinese Fosun deal. They raise their valuation of RENE from 608p per share, to 630p per share. Note that valuation was made 2 weeks ago before today's good news which will have firmed up the valuation a little !

QUOTE: Following-on from ReNeuron’s recent striking early-stage data release for its human retinal progenitor cell (hRPC) product in retinitis pigmentosa (RP), and the ongoing partnering interest in cellular therapies, ReNeuron has partnered its two lead products – hRPC and the CTX cell line – for the Chinese market with Fosun Pharma. We have updated our model to reflect the near-term part of the £80m in potential total upfront payments and milestones.
Open season on cellular therapies
After the acquisition of two US chimeric antigen receptor T-cell (CAR-T) companies, Kite and Juno, in 2017 for $12bn and $8bn, respectively, cellular therapies have become a rich source of licensing and acquisition transactions. With two products in two clinical studies and an exosome platform, it was probably only a matter of time before ReNeuron announced its first deal of 2019. While ReNeuron’s first transaction covers two products for the Chinese market, the rest of the world remains available and it is unlikely that this will be the last such transaction it announces. Our model anticipates a further £10m transaction before year end 2020.
Fosun licenses ReNeuron’s lead products for China
In a well-received press release, ReNeuron announced the licence of its two lead products – the CTX and hRPC cell therapy programmes for chronic stroke and degenerative retinal diseases, respectively – to Shanghai and Hong Kong-listed Shanghai Fosun Pharmaceutical Industrial for the Chinese market. The transaction includes a £6m upfront payment, an additional £6m in near-term operational milestones and a further £8m in future regulatory milestone payments that together with post-launch profit milestones, could be worth up to £80m in total. The deal also includes tiered royalties of between 12% and 14% of Chinese sales and Fosun is fully funding the development and commercialisation of ReNeuron’s products in China.
Valuation: Updated for the Fosun transaction
Our previous model did not include Chinese sales for ReNeuron’s CTX or hRPC products, so we have added these with some conservative assumptions for penetration and pricing in China, and have used the epidemiology from Japan. In our model we have approximated the announced milestone flow up to launch in China as other income, but left the probabilities of success for both CTX and hRPC unchanged at 25% and 20%, respectively. Our valuation moves from £192m or 608p per share, to £199m or 630p per share.

Edison Research which follows RENE, has released a positive update today:

QUOTE ReNeuron has released further data on the first three retinitis pigmentosa (RP) patients dosed with its human retinal progenitor cell (hRPC) product. Improvements in visual acuity have continued to the 60- and 120-day follow-up points. Although further and longer-duration data would be required for a regulator to consider an accelerated regulatory strategy, potential partners for the ex-China rights to ReNeuron’s hRPC product could act much sooner.

Our late February note on ReNeuron’s first announcement of the striking but early data for its hRPC product in three RP patients discussed the surprising 20-letter (in a standardised eye chart used in ophthalmic examinations) improvement at two months for the first patient, and 15- and 14-letter improvements at 18 days for the second and third patients. The data being presented at the Retinal Cell and Gene Therapy Innovation Summit demonstrated the maintenance of the visual acuity previously reported as well as continued improvements out to the 120- and 60-day time points for the first and subsequent two patients respectively.

While ReNeuron has already started dosing the second cohort of three patients, the durability of the early response in the first cohort and the continuing improvement in visual acuity in all three patients are almost certainly better data than many investors would have expected. Investors may remember that ReNeuron partnered the rights to the hRPC and CTX cellular therapy products in China with Fosun in early April, and although the data are still too immature for a discussion of an accelerated regulatory filing, the likelihood of additional commercial partnerships after each positive announcement of the hRPC programme increases. ENDQUOTE

There's small free float of shares in RENE, with long term holders inc. Woodford. Also, many of us private investors have held for many years. Having stuck with it this length of time, I doubt those shares inc. my own will be up for sale.

There will be short-term wobbles - that's for day-traders too worry about - but if one can shut one's eyes and look again at year-end, then you'll be OK.

QUOTE: Sarah Neville, Global Pharmaceuticals Editor April 9, 2019
Shares in ReNeuron, a company working on stem-cell treatments for eye disease and strokes that is one-third owned by veteran investor Neil Woodford, rose more than 30 per cent on Tuesday, after it announced a licensing deal for its products to be developed and commercialised in China. Fosun Pharma, a Chinese life sciences company, will licence the rights to two cell therapy programmes in a deal that will potentially net the UK-based biotech £80m, plus royalty payments. Yifang Wu, President of Fosun Pharma, said ReNeuron’s licensed products and stem cell expertise would “bring a lot of strategic synergies with our current business, addressing huge unmet needs in the Chinese market”.

One of the two ReNeuron programmes licensed by Fosun Pharma involves the treatment of retinitis pigmentosa, a genetic eye defect that affects about 100,000 people in the US alone. Olav Hellebo, ReNeuron’s chief executive, said that in clinical studies, patients had been able to read three additional lines, or 15 letters, on an eye-test chart after treatment with the company’s stem cells, an improvement that was considered “very significant”. It suggested that the treatment might be creating new photoreceptors in the eyes, a response that had not been seen before, he said. The US Food and Drug Administration is fast-tracking the therapy for approval, in recognition of the lack of any current effective treatments for RP.

ReNeuron is also holding trials of a treatment for people who have lost movement after a stroke, a therapy that involves an injection of neurological stem cells. While the wider field of cell and gene therapy has been growing rapidly in recent years, few companies are yet undertaking pure stem-cell therapy. Mr Hellebo said this partly reflected the typical pharma development cycle. “When stem cells came in 10 or 20 years ago, [they were] completely overhyped, then everyone lost interest because it turned out to to be really difficult?.?.?.?but now it’s coming back because we have figured how to get the quality right, how to do the manufacturing right, and we are starting to get some good quality data.” The deal in China offered access to “a very large market and it’s a market that we could never tackle on our own” he said.

Fosun Pharma will fully fund the development of ReNeuron’s eye disease and stroke cell therapy programmes in China, including clinical development and commercialisation. It has also been granted rights to manufacture the licensed products in China. ENDQOUTE

I'm taken with the comment by one of the Study Investigators:

Pravin Dugel MD, Managing Partner, Retinal Consultants of Arizona, Phoenix, Arizona, and Clinical Professor, Roski Eye Institute, USC Keck School of Medicine, Los Angeles, California, and study investigator, commented:

"I am excited that the rapid and remarkable visual improvement in these RP patients has been sustained and even improved upon at 60 and 120 days. It is especially gratifying to feel the excitement and joy in my patients where this objective and subjective improvement in their vision has been a source of hope following years of slow but steady progression towards blindness."

CORO presentation at the end March investor show at Westminster has been released.
CFO Andrew Dennan made a very strong, upbeat presentation as can clearly be seen here. He shows us a very enthusiatic attitude towards the company and is clearly confident as to his facts.

https://www.ukinvestorshow.com/videos/coro-energy-plc/

Drax - you mean £5.47 a share (100:1 consolidation).

I'm very much expecting to get that this year - albeit may be much nearer the end of the year.

There's no doubting that DRAX - your'e quite right to remind us of the wonderful prospect for these patients - but many of us have been in RENE for many years. Mine goes back 2012 around the 3p+ mark, peaking at just under 6p - ie £6 in todays's money so I would mind getting that back if possible please.

"That's it. I'm not expecting anything more than that, but that would be explosive in of itself I should think."

I agree guys - Rene for 40p sums it up - it's continued indicators of progress in the small cohort of patients that are currently receiving treatment that we want to hear about. In my opinion, it doesn't necessarily need to be mind blowing news but even modest progress will be good news all round.

Last year's full results for y/e Nov18 came out 19th May.

It's the post y/e activity that we'll all be watching as there have been so very many trading/licensing agreements completed these past 18 months, that income must start to be accruing now. I'm not expecting massive numbers but some reassurance that sales are happening.

I feel that the current sp is the floor and we should start to recover sp momentum again given the Director purchases and options to new Directors given at the higher levels. Such as Non-exec Chairman now holding 478,000 - the last 103,000 purchased at 98.6p and Sean Christie Non-Exec Director given options at 95p.

I topped up my holding with a few more this afternoon 5000 @ 78.2p and I'm very positive but each to his own.

Thanks Thomas for update.

I see there was a large buy late this afternoon giving rise to a firming of the SP.

Malcolm is very positive about CEO James Menzies - but his enthusiasm for CORO reflects his keeness on JM and the fact is the recent acquisition deal got turned down by the would-be candidate. Is it only such deals that will lift this share back to where it started just a couple of years ago ?

Specific time for Coro discussion starts at: 31mins 50secs

. . . in recent comments.

Yes anything is possible with AIM shares but anyone who has been through the last 5 or more years with RENE will tell you it's been uncomfortable to say the least.

Certainly we look for positive news from the US trials currently taking place but isn't that already in the picture ?
I would just caution new investors as the real news won't be announced until nearer year end.

Dar - You can download the Annual Report from here:

https://www.tpgroup.uk.com/investors/

The video of the 20 mins presentation at the 30th March Westminster Show has been released.
Having bought in at 4p a while back, I had hoped to get to the show but a rail problem prevented it. Then, when the placing at 3p occurred a short period following the show, I must admit to being concerned and wondered why the discount had to be so large.

This presentation answers most of my doubts and the prospects imo ook good - the next few weeks will answer the few doubts remaining:

https://www.ukinvestorshow.com/videos/concepta-plc/

Another Director purchase today 10,000 @ 228p
That has to be good news along with the other Non-Execs recently - that always speaks volumes.